Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jan 1;119(1):90-8.
doi: 10.1002/cncr.27617. Epub 2012 Jun 28.

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802

Wendy Stock  1 , Jeffrey L Johnson, Richard M Stone, Jonathan E Kolitz, Bayard L Powell, Meir Wetzler, Peter Westervelt, Guido Marcucci, Daniel J DeAngelo, James W Vardiman, Diane McDonnell, Krzysztof Mrózek, Clara D Bloomfield, Richard A Larson
Affiliations
Clinical Trial

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802

Wendy Stock et al. Cancer. .

Erratum in

Abstract

Background: Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and whether high-dose systemic and intrathecal methotrexate could replace cranial radiotherapy for central nervous system (CNS) prophylaxis.

Methods: One hundred sixty-one eligible, previously untreated patients ages 16 to 82 years (median age, 40 years) were enrolled, and 33 (20%) were aged ≥60 years.

Results: One hundred twenty-eight patients (80%) achieved complete remission (CR). Dose intensification of daunorubicin and cytarabine was feasible. At a median follow-up of 10.4 years for surviving patients, the 5-year DFS rate was 25% (95% confidence interval, 18%-33%), and the overall survival (OS) rate was 30% (95% confidence interval, 23%-37%). Patients aged <60 years who received the 80 mg/m(2) dose of daunorubicin had a DFS of 33% (95% confidence interval, 22%-44%) and an OS of 39% (95% confidence interval, 29%-49%) at 5 years. Eighty-four patients (52%) relapsed, including 9 patients (6%) who had isolated CNS relapses. The omission of cranial irradiation did not result in higher than historic CNS relapse rates.

Conclusions: Intensive systemic, oral, and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL. This intensive approach using higher doses of daunorubicin and cytarabine failed to result in an overall improvement in DFS or OS compared with historic CALGB studies. Future therapeutic strategies for adults with ALL should be tailored to specific age and molecular genetic subsets.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Treatment plan
Figure 2
Figure 2. a. and b. Disease-free survival and Overall Survival
One hundred and twenty-eight patients (80%) of the 161 enrolled onto CALGB 19802 achieved CR. The 5-year DFS was estimated at 25% (95% CI, 18–33%) (Figure 2a). Overall survival at 5-years for all 161 patients was 30% (95% CI, 23–37%) (Figure 2b).
Figure 2
Figure 2. a. and b. Disease-free survival and Overall Survival
One hundred and twenty-eight patients (80%) of the 161 enrolled onto CALGB 19802 achieved CR. The 5-year DFS was estimated at 25% (95% CI, 18–33%) (Figure 2a). Overall survival at 5-years for all 161 patients was 30% (95% CI, 23–37%) (Figure 2b).
Figure 3
Figure 3. a. b, c and d. DFS and OS by age and cytogenetic risk group
Disease-free survival (Figure 3a) and overall survival (Figure 3b) by age. Disease-free survival (Figure 3c) and overall survival (Figure 3d) by cytogenetic risk group.
Figure 3
Figure 3. a. b, c and d. DFS and OS by age and cytogenetic risk group
Disease-free survival (Figure 3a) and overall survival (Figure 3b) by age. Disease-free survival (Figure 3c) and overall survival (Figure 3d) by cytogenetic risk group.
Figure 3
Figure 3. a. b, c and d. DFS and OS by age and cytogenetic risk group
Disease-free survival (Figure 3a) and overall survival (Figure 3b) by age. Disease-free survival (Figure 3c) and overall survival (Figure 3d) by cytogenetic risk group.
Figure 3
Figure 3. a. b, c and d. DFS and OS by age and cytogenetic risk group
Disease-free survival (Figure 3a) and overall survival (Figure 3b) by age. Disease-free survival (Figure 3c) and overall survival (Figure 3d) by cytogenetic risk group.
Figure 4
Figure 4. a and b. DFS and OS by daunorubicin dose for patients < 60 years old
Complete remission was achieved in 36 of 39 (92%) patients who received the 60 mg/m2 daily dose of daunorubicin. Five-year DFS for these patients was estimated at 18% (95% CI,7–32%) and OS was 29% (16–44%). For the 89 patients who received the 80 mg/m2 daily daunorubicin dose, CR was achieved in 72 (81%). The 5-year DFS for these patients was 33% (95% CI, 22–44%) and OS was 39% (29–49%).
Figure 4
Figure 4. a and b. DFS and OS by daunorubicin dose for patients < 60 years old
Complete remission was achieved in 36 of 39 (92%) patients who received the 60 mg/m2 daily dose of daunorubicin. Five-year DFS for these patients was estimated at 18% (95% CI,7–32%) and OS was 29% (16–44%). For the 89 patients who received the 80 mg/m2 daily daunorubicin dose, CR was achieved in 72 (81%). The 5-year DFS for these patients was 33% (95% CI, 22–44%) and OS was 39% (29–49%).
See this image and copyright information in PMC

References

    1. Bassan R, Pogliani E, Casula P, et al. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. Hematol J. 2001;2(2):117–126. - PubMed
    1. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL) Hematol Oncol Clin North Am. 2000 Dec;14(6):1307–1325. ix. - PubMed
    1. Hofmann WK, Seipelt G, Langenhan S, et al. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol. 2002 Oct;81(10):570–574. - PubMed
    1. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 Dec 15;101(12):2788–2801. - PubMed
    1. Larson RA. The U.S. trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004;83(Suppl 1):S127–S128. - PubMed

Publication types

MeSH terms